Oxaprozin disposition in renal disease.
Effects of renal disease on the disposition kinetics of oxaprozin, a nonsteroidal antiinflammatory analgesic, were assessed in 15 subjects who were normal, renally impaired, or who had been undergoing hemodialysis. Oral dose clearance (Cloral), volume of distribution at steady-state (V88d), and elimination half-life (t 1/2) did not substantially differ among the three groups. Mean fraction unbound oxaprozin in plasma (fup) increased from 0.08% in the normal group to 0.18% and 0.28% in the two azotemic groups. Consequently, unbound drug kinetic parameters, including intrinsic clearance (Clint) and V88du of unbound drug were reduced from 2.9 l/hr/kg and 193 l/kg in normal subjects to approximately 1.6 l/hr/kg and 91 l/kg in azotemic patients. The smaller volume of distribution is consistent with a decrease in oxaprozin tissue binding in azotemia. The decreased plasma and tissue binding and lower Clint suggest that, in the treatment of azotemic patients with rheumatoid arthritis, the dose of oxaprozin should begin at 600 mg once a day.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D000077431:Oxaprozin; D010080:Oxazoles / Q000378:metabolism*; D011422:Propionates / Q000378:metabolism*; D011485:Protein Binding
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D010080:Oxazoles; D011422:Propionates; D000077431:Oxaprozin